Skip to main content Skip to section navigation Skip to footer
Back to scorpiusbiologics.com
Scorpius Holdings, Inc. Home
Investor Relations
  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Company Profile
    • Executive Team
    • Contacts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • At-a-Glance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Back to scorpiusbiologics.com

Press Releases

News & Events

News & Events

  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Mar 16, 2020 8:00 am EDT

Heat Biologics Invited to Join The Alliance for Biosecurity

Mar 05, 2020 4:45 pm EST

Heat Biologics, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City

Mar 05, 2020 9:00 am EST

Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Mar 04, 2020 3:10 pm EST

Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company’s Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19

Mar 03, 2020 8:00 am EST

Heat Biologics Launches Program to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

Jan 21, 2020 4:05 pm EST

Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

Jan 16, 2020 9:50 am EST

Heat Biologics, Inc. Prices $7,000,000 Public Offering

Dec 16, 2019 7:00 am EST

Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

Nov 20, 2019 8:00 am EST

Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Nov 18, 2019 8:00 am EST

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
©2025 Scorpius Holdings, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences